At IAS 2025, ViiV’s Jean van Wyk, MBChB, MFPM, shares how real-world data and patient priorities are guiding a new era of HIV care.
Jean van Wyk, MBChB, MFPM
Advertisement
Chief Medical Officer at ViiV Healthcare
Articles by Jean van Wyk, MBChB, MFPM
At IAS 2025, the VOLITION and OPERA study data show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.
Advertisement
Latest Updated Articles
Long-Acting HIV Therapy Gains Ground in Both New and Experienced PatientsPublished: July 14th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
2
Cefiderocol is Noninferior, But not "Game-Changer," for Gram-negative Bloodstream Infections
3
Misdiagnosis Common in Skin Infections Due to Overlapping Noninfectious Conditions
4
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
5
